Celyad SA (CYAD) IPO Prices at $68.56/ADS

Celyad raises $100.1 million gross proceeds with NASDAQ IPO

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--

Regulatory News:

Celyad SA (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris: CYAD), today announced the pricing of its global offering totaling $100.1 million gross proceeds of 1,460,000 new ordinary shares, consisting of 1,168,000 American Depositary Shares (ADSs) at $68.56 per ADS, and 292,000 ordinary shares at a price of EUR 60.25 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the United States and private placement in Europe (together the global offering). The price per ADS was based on EUR 60.25 per ordinary share at an exchange rate of $ 1.1380 per... More

Celyad Raises $100.1 Million Gross Proceeds With NASDAQ IPO

MONT-SAINT-GUIBERT, Belgium, June 18, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Euronext Brussel: CYAD) (Paris: CYAD), today announced the pricing of its global offering totaling $100.1 million gross proceeds of 1,460,000 new ordinary shares, consisting of 1,168,000 American Depositary Shares ("ADSs") at $68.56 per ADS, and 292,000 ordinary shares at a price of EUR 60.25 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the United States and private placement in Europe (together the "global offering"). The price per ADS was based on EUR 60.25 per... More